HROW beat EPS expectations by 22.14%
Nov 10, 2025, 11:37 PM
0.00%
What does HROW do
Harrow, headquartered in Nashville, Tennessee, develops and sells innovative ophthalmic medications and operates ImprimisRx, employing 315 staff since its IPO on February 8, 2013. The company markets various prescription products, including VIGAMOX and IHEEZO.
Harrow (HROW) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Harrow's actual EPS was $0.22, beating the estimate of $0.27 per share, resulting in a 22.14% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.